OTCMKTS:CPHRF

Cipher Pharmaceuticals (CPHRF) Stock Forecast, Price & News

$3.18

-0.05 (-1.55%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.50
▼
$3.19
50-Day Range: $2.56
▼
$3.34
52-Week Range: $1.31
▼
$5.38

Volume: 9,000 shs
Average Volume: 6,536 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

CPHRF Price History

30 days | 90 days | 365 days | Advanced Chart

CPHRF Stock News Headlines

September 22, 2023 | americanbankingnews.com

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Above 50-Day Moving Average of $2.88

June 1, 2023 | markets.businessinsider.com

Cipher Pharmaceuticals (CPHRF) Receives a Buy from Stifel Nicolaus

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

May 17, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc up on Wednesday (CPH)

May 11, 2023 | seekingalpha.com

Cipher Pharmaceuticals GAAP EPS of $0.10 beats by $0.02, revenue of $4.9M misses by $0.64M

May 11, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial Flexibility

May 2, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc down on Tuesday (CPH)

May 2, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc up on Monday (CPH)

September 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

April 27, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc down on Thursday (CPH)

April 21, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc down on Friday (CPH)

April 7, 2023 | theglobeandmail.com

Closing Bell: Cipher Pharmaceuticals Inc up on Thursday (CPH)

March 20, 2023 | seekingalpha.com

Cipher Pharmaceuticals Inc. (CPHRF) Q4 2022 Earnings Call Transcript

March 17, 2023 | markets.businessinsider.com

Cipher Pharmaceuticals earnings: here's what Wall Street expects

March 10, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q4 2022 Earnings Release and Conference Call

January 31, 2023 | finance.yahoo.com

Cipher Pharmaceuticals (TSE:CPH) shareholders have earned a 51% CAGR over the last three years

January 13, 2023 | finanznachrichten.de

Cypher Core, Inc: CIPHER-CORE, Inc. President Addresses Company's Business Direction

November 11, 2022 | ca.finance.yahoo.com

Cipher Pharmaceuticals Inc. (CPHRF)

November 10, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Reports Strong Third Quarter Results, Highlighted by USD$1.09 in Cash Per Share

August 24, 2022 | finance.yahoo.com

Investing in Cipher Pharmaceuticals (TSE:CPH) three years ago would have delivered you a 107% gain

August 12, 2022 | seekingalpha.com

Cipher Pharmaceuticals Inc. (CPHRF) CEO Craig Mull on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Strengthens Leadership Team with Appointment of New CFO

July 9, 2022 | theglobeandmail.com

Cipher Pharmaceuticals Inc stock boosted on Friday.

May 14, 2022 | seekingalpha.com

Cipher Pharmaceuticals GAAP EPS of C$0.08, revenue of C$5.4M

March 24, 2022 | finance.yahoo.com

Is Now The Time To Put Cipher Pharmaceuticals (TSE:CPH) On Your Watchlist?

March 22, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

March 18, 2022 | benzinga.com

MariMed Doubles Full Year Revenue And Adjusted EBITDA, Reports Q4 & Full Year Earnings

See More Headlines

Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPHRF Company Calendar

Last Earnings: 5/05/2016
Today: 9/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CPHRF
Previous Symbol: NASDAQ:CPHR
CUSIP: N/A
CIK: N/A
Web: www.cipherpharma.com
Phone: (905) 602-5840
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Craig J. Mull
Interim CEO & Chairman

Mr. Bryan Jacobs
Chief Financial Officer

Dr. Diane Gajewczyk
VP of Scientific & Medical Affairs

Mr. Emilio Presti
Director of Sales & Marketing

Key Competitors

View All Competitors

CPHRF Stock - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPHRF shares.
View CPHRF analyst ratings or view top-rated stocks.
How have CPHRF shares performed in 2023?: Cipher Pharmaceuticals' stock was trading at $2.7949 at the beginning of 2023. Since then, CPHRF shares have increased by 13.9% and is now trading at $3.1847.
View the best growth stocks for 2023 here.
Are investors shorting Cipher Pharmaceuticals?: Cipher Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,100 shares, a drop of 15.4% from the August 31st total of 1,300 shares. Based on an average trading volume of 16,300 shares, the short-interest ratio is currently 0.1 days.
View Cipher Pharmaceuticals' Short Interest.
How were Cipher Pharmaceuticals' earnings last quarter?: Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The company earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million.

What is Cipher Pharmaceuticals' stock symbol?: Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."
How do I buy shares of Cipher Pharmaceuticals?: Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cipher Pharmaceuticals' stock price today?: One share of CPHRF stock can currently be purchased for approximately $3.18.
How can I contact Cipher Pharmaceuticals?: Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at (905) 602-5840.

This page (OTCMKTS:CPHRF) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial